Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(22):1656-1657; doi:10.1093/jnci/95.22.1656
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Goldman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldman, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

NEWS

Combinations of Targeted Therapies Take Aim at Multiple Pathways

Bruce Goldman

The first 10% of the full text of this article appears below.

First in a two-part series.

Novel targeted agents—compounds designed to hit either a single pathway or, in some cases, multiple pathways that control a cancer cell’s ability to grow and escape conventional therapy—are raising hopes that cancer can be treated with more precision and fewer side effects than has been possible with more conventional cytotoxic drugs.

However, "targeted" is a relative term. The old-line cytotoxics are "targeted," too. But their targets are, metaphorically speaking, the broad side of a barn; for instance, the drugs may target DNA in rapidly dividing cells, transformed and healthy alike. In contrast, targeted therapies are designed to preferentially destroy cancer cells by keying in on abnormalities essential to those cells’ survival and proliferation, thus shrinking tumors while sparing normal cells.

Cytotoxic drugs have been tested and used in various combinations for decades. So why . . . [Full Text of this Article]

Many Approved Therapies

Combination Trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Dai, T. Wan, B. Wang, X. Zhou, F. Xiu, T. Chen, Y. Wu, and X. Cao
More Efficient Induction of HLA-A*0201-Restricted and Carcinoembryonic Antigen (CEA)-Specific CTL Response by Immunization with Exosomes Prepared from Heat-Stressed CEA-Positive Tumor Cells
Clin. Cancer Res., October 15, 2005; 11(20): 7554 - 7563.
[Abstract] [Full Text] [PDF]